268 related articles for article (PubMed ID: 34989724)
21. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
[TBL] [Abstract][Full Text] [Related]
22. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma.
Prados MD; Scott CB; Rotman M; Rubin P; Murray K; Sause W; Asbell S; Comis R; Curran W; Nelson J; Davis RL; Levin VA; Lamborn K; Phillips TL
Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):653-9. PubMed ID: 9486616
[TBL] [Abstract][Full Text] [Related]
23. Nanotechnology meets glioblastoma multiforme: Emerging therapeutic strategies.
Liu D; Dai X; Ye L; Wang H; Qian H; Cheng H; Wang X
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023 Jan; 15(1):e1838. PubMed ID: 35959642
[TBL] [Abstract][Full Text] [Related]
24. A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses.
Gomez-Roman N; Stevenson K; Gilmour L; Hamilton G; Chalmers AJ
Neuro Oncol; 2017 Feb; 19(2):229-241. PubMed ID: 27576873
[TBL] [Abstract][Full Text] [Related]
25. Drug Delivery Nanosystems in Glioblastoma Multiforme Treatment: Current State of the Art.
Di Filippo LD; Duarte JL; Luiz MT; de Araújo JTC; Chorilli M
Curr Neuropharmacol; 2021; 19(6):787-812. PubMed ID: 32867643
[TBL] [Abstract][Full Text] [Related]
26. Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma.
Narayan RS; Gasol A; Slangen PLG; Cornelissen FMG; Lagerweij T; Veldman HYYE; Dik R; van den Berg J; Slotman BJ; Würdinger T; Haas-Kogan DA; Stalpers LJA; Baumert BG; Westerman BA; Theys J; Sminia P
Mol Cancer Ther; 2018 Feb; 17(2):347-354. PubMed ID: 28958992
[TBL] [Abstract][Full Text] [Related]
27. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
28. Lipid-Based Nanocarriers in the Treatment of Glioblastoma Multiforme (GBM): Challenges and Opportunities.
Gupta T; Sahoo RK; Singh H; Katke S; Chaurasiya A; Gupta U
AAPS PharmSciTech; 2023 Apr; 24(4):102. PubMed ID: 37041350
[TBL] [Abstract][Full Text] [Related]
29. Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology.
Rezaei V; Rabiee A; Khademi F
J Chemother; 2020 May; 32(3):107-117. PubMed ID: 31984871
[TBL] [Abstract][Full Text] [Related]
30. Harnessing nanomedicine for therapeutic intervention in glioblastoma.
Gutkin A; Cohen ZR; Peer D
Expert Opin Drug Deliv; 2016 Nov; 13(11):1573-1582. PubMed ID: 27292970
[TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up on National Cancer Institute Phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation.
Goffman TE; Dachowski LJ; Bobo H; Oldfield EH; Steinberg SM; Cook J; Mitchell JB; Katz D; Smith R; Glatstein E
J Clin Oncol; 1992 Feb; 10(2):264-8. PubMed ID: 1310102
[TBL] [Abstract][Full Text] [Related]
32. Tumor cell-targeting radiotherapy in the treatment of glioblastoma multiforme using linear accelerators.
Chiang CS; Shih IJ; Shueng PW; Kao M; Zhang LW; Chen SF; Chen MH; Liu TY
Acta Biomater; 2021 Apr; 125():300-311. PubMed ID: 33609743
[TBL] [Abstract][Full Text] [Related]
33. Breaching barriers in glioblastoma. Part II: Targeted drug delivery and lipid nanoparticles.
Miranda A; Blanco-Prieto MJ; Sousa J; Pais A; Vitorino C
Int J Pharm; 2017 Oct; 531(1):389-410. PubMed ID: 28801108
[TBL] [Abstract][Full Text] [Related]
34. The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update.
Ziu M; Kim BYS; Jiang W; Ryken T; Olson JJ
J Neurooncol; 2020 Nov; 150(2):215-267. PubMed ID: 33215344
[TBL] [Abstract][Full Text] [Related]
35. Theranostic nanoparticles enhance the response of glioblastomas to radiation.
Wu W; Klockow JL; Mohanty S; Ku KS; Aghighi M; Melemenidis S; Chen Z; Li K; Morais GR; Zhao N; Schlegel J; Graves EE; Rao J; Loadman PM; Falconer RA; Mukherjee S; Chin FT; Daldrup-Link HE
Nanotheranostics; 2019; 3(4):299-310. PubMed ID: 31723547
[TBL] [Abstract][Full Text] [Related]
36. Use of nanoparticles for drug delivery in glioblastoma multiforme.
Jain KK
Expert Rev Neurother; 2007 Apr; 7(4):363-72. PubMed ID: 17425491
[TBL] [Abstract][Full Text] [Related]
37. Radiotherapy and chemotherapy with or without carbogen and nicotinamide in inoperable biopsy-proven glioblastoma multiforme.
Simon JM; Noël G; Chiras J; Hoang-Xuan K; Delattre JY; Baillet F; Mazeron JJ
Radiother Oncol; 2003 Apr; 67(1):45-51. PubMed ID: 12758239
[TBL] [Abstract][Full Text] [Related]
38. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
39. Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma.
Bastiancich C; Danhier P; Préat V; Danhier F
J Control Release; 2016 Dec; 243():29-42. PubMed ID: 27693428
[TBL] [Abstract][Full Text] [Related]
40. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Alshami J; Guiot MC; Owen S; Kavan P; Gibson N; Solca F; Cseh A; Reardon DA; Muanza T
Oncotarget; 2015 Oct; 6(32):34030-7. PubMed ID: 26423602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
